Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia
Part of paid clinical trials in Lauderdale Lakes, Florida.
- Sponsor
- Ardelyx
- Study ID
- NCT04549597
- Phase
- PHASE4
- Status
- Completed
Conditions
- Chronic Kidney Disease Requiring Chronic Dialysis
- Hyperphosphatemia
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 90 Years
- Healthy Volunteers
- Not accepted
Interventions
- Tenapanor — DRUGUse of tenapanor
Study Details
This is a randomized, open-label study to evaluate different methods of initiating tenapanor therapy in CKD patients on dialysis with hyperphosphatemia, when they are either phosphate binder naïve or on phosphate binder therapy. The objective to evaluate the effect of tenapanor alone or in combination with phosphate binders to achieve target serum phosphorus (s-P) levels of ≤5.5 mg/dL when tenapanor is administered as the core therapy (alone or in combination with phosphate binders) for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.
Key Dates
- Start date
- Nov 20, 2020
- Status verified
- Mar 2023
- Primary completion
- Oct 13, 2021
- Completion
- Dec 1, 2021
Study Design
- Enrollment
- 333 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Cohort 1: Straight SwitchPatients stop taking phosphate binders and start tenapanor 30 mg twice daily
- Experimental: Cohort 2: Decrease Phosphate Binder by 50%Decreases phosphate binder dose by at least 50% with the ability to switch the binder regiment from thrice daily (TID) to BID or once a day and initiates tenapanor 30 mg BID
- Experimental: Cohort 3: Phosphate Binder NaivePhosphate binder naive patients are enrolled as Cohort 3 and receive tenapanor with a starting dose of 30 mg/BID
Primary Outcome Measure
Effect of Tenapanor to Achieve Target s-P Levels of Less Than or Equal to 5.5 mg/dL [ Time Frame: 10 weeks ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| South Florida Research Institute | Lauderdale Lakes | Florida | 33313 | - |
Find similar trials in Lauderdale Lakes, FL
Related Studies
- Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)Recruiting · Duke University · Phoenix, Arizona
- A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With HyperphosphatemiaPHASE2 · Recruiting · R1 Therapeutics · Huntsville, Alabama
- A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and ChinaPHASE3 · Recruiting · Alebund Pharmaceuticals · Granada Hills, California